Supplements With Evidence In Mild Cognitive Impairment
Quick Read Mild cognitive impairment is a grey zone between normal age-related memory changes and dementia, and it may be
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
Niacin, a B vitamin, has been studied for 70 years as a heart health tool. Early research showed it could lower cholesterol and reduce heart attacks, but more recent large trials found it didn’t add much benefit when combined with statins, which most heart patients already take. The picture became more complicated in 2024, when researchers discovered that excess niacin produces metabolites (byproducts) linked to increased cardiovascular risk and vascular inflammation.
However, getting adequate niacin from food appears genuinely protective, particularly for women, and taking a standard B-complex supplement is safe and beneficial. The concern is specifically about high-dose niacin supplements or therapy (gram-scale doses), not everyday sources or modest supplementation.
The current scientific consensus is clear: eat niacin-rich foods like chicken, fish, wholegrains and nuts; take a balanced B-complex supplement if you wish; but avoid self-prescribing high-dose niacin without medical guidance. The field is also tracking an exciting newer angle on niacin’s role in supporting NAD+, a molecule critical to how heart cells produce energy as we age.
Verdict: Dietary niacin is genuinely protective, standard supplementation is safe, but high-dose niacin therapy requires medical supervision, especially given emerging evidence about harmful metabolites from excess intake.
What if one of the most important chapters in the history of heart health research began not with a billion-dollar drug, but with a humble B vitamin that most people associate with keeping their energy levels up? And what if that same vitamin, studied more extensively than almost any other nutrient in cardiovascular science, has recently thrown researchers a curveball that nobody saw coming?
The story of niacin and cardiovascular health is one of the most fascinating, contested and genuinely illuminating journeys in modern medicine. It starts in 1955, when a physician named Rudolf Altschul first reported that large doses of nicotinic acid, the form of niacin used therapeutically, could dramatically lower cholesterol levels in humans. At a time when heart disease was beginning its rise to become the world’s leading killer, this was enormous news. For the next five decades, niacin was not just studied, it was celebrated. And then, just as science tends to do, it got complicated.
Here at Vitacuity, we’ve analysed over 1.77 million research papers and selected the most relevant findings on this topic to bring you a complete, honest picture. What emerges is not a story of failure, it’s a story of discovery, nuance, and a genuinely evolving science that has taught us more about the heart, cholesterol, and metabolism than almost any other single nutrient. Let’s walk through it together.
Niacin, also known as vitamin B3, is an essential micronutrient that your body uses to produce NAD+ (nicotinamide adenine dinucleotide), a molecule absolutely central to energy metabolism in every cell, including the billions of cells that make up your cardiovascular system [8].
But at pharmacological doses, far above what you’d get from food, niacin does something remarkable to your blood lipid profile. It works through several distinct mechanisms [9]:
– It reduces triglycerides by decreasing the release of fatty acids from fat tissue, and by inhibiting an enzyme in the liver (diacylglycerol acyltransferase) involved in fat synthesis, meaning the liver produces and secretes fewer VLDL and LDL particles. – It lowers LDL cholesterol by increasing the breakdown of a key protein (apolipoprotein B) inside liver cells, leading to fewer harmful particles being released into the bloodstream. – Perhaps most significantly, it raises HDL cholesterol, the so-called “good” cholesterol, by slowing the rate at which HDL is removed from the blood, and specifically increasing a protective subfraction of HDL called Lp-AI, which is particularly effective at the process of reverse cholesterol transport (essentially, ferrying cholesterol away from artery walls and back to the liver for disposal) [9].
For decades, this triple-action lipid profile looked like a cardiovascular goldmine. No other single agent, vitamin or drug, could claim to do all three simultaneously. By 2011, one review was bold enough to describe niacin as “the only vitamin that reduces cardiovascular events” [6].
But that was 2011. Science kept going. And here’s what we’ve learned since.
The landmark Coronary Drug Project, one of the largest cardiovascular trials ever conducted at the time, followed over 8,000 men with previous heart attacks across multiple US centres. Among its treatment arms was high-dose niacin. The results, which emerged in the 1970s, were striking: niacin reduced non-fatal heart attacks by around 27% compared to placebo, a meaningful, real-world reduction in serious cardiac events.
Remarkably, a follow-up analysis conducted years after the trial ended found that participants who had been on niacin actually had significantly lower total mortality rates even 15 years later, a finding that cemented niacin’s reputation as a genuinely cardioprotective nutrient at that time [10].
The evidence grade for this era: Promising to Strong, large trial, real clinical outcomes, meaningful effect sizes.
This was also the period when researchers began to understand the blood pressure angle. A 2009 review examining niacin’s effects on blood pressure found that both immediate-release and extended-release forms may lower blood pressure over time, with the Coronary Drug Project data suggesting a chronic, dose-dependent BP-lowering effect, adding another potential cardiovascular benefit to niacin’s already impressive CV profile [12].
When statins arrived in the 1990s and revolutionised LDL management, you might expect niacin’s moment to have passed. But instead, it had a second act, because statins don’t raise HDL. And HDL, the research strongly suggested, was an independent risk factor for heart disease.
Niacin remained, throughout the 2000s, the most potent HDL-raising agent available, capable of increasing HDL by 15–35% depending on dose [10, 11]. For patients who had already achieved good LDL control on statins but still carried elevated cardiovascular risk due to low HDL or high triglycerides, niacin appeared to be a logical and evidence-backed adjunct therapy.
A 2011 review noted that several studies had shown benefits of niacin combined with statin therapy on surrogate cardiovascular markers, including carotid intima-media thickness, a measure of arterial wall thickening considered a strong predictor of future events [10]. The field was optimistic. Extended-release formulations (brand name Niaspan) were developed to reduce the notorious side effect of skin flushing, a prostaglandin-mediated response that made high-dose niacin uncomfortable for many patients [13]. A new compound called laropiprant was developed specifically to block the flushing response, and the combination of extended-release niacin with laropiprant was heralded as a breakthrough in making niacin therapy tolerable at scale [13].
The evidence grade at this stage: Promising, strong lipid biomarker data, some early outcome data, growing mechanistic understanding.
This is where the story gets genuinely interesting, and where intellectual honesty matters enormously.
Two large randomised controlled trials, AIM-HIGH and HPS2-THRIVE, were designed to definitively answer whether adding niacin to statin therapy reduced hard cardiovascular outcomes (heart attacks, strokes, deaths). Both were stopped early, and neither showed a significant reduction in major cardiovascular events compared to statin therapy alone [7, 11].
This was, understandably, a shock to the field. A 2017 Cochrane-style review of niacin for primary and secondary prevention confirmed the controversial picture: while niacin demonstrably improves lipid biomarkers, the evidence for translating those improvements into fewer actual cardiovascular events, particularly when added to statins, was not consistent [7].
Why did the trials conflict with earlier data? This is the critical question, and the honest answer involves several factors:
1. Era of medicine matters enormously. The landmark Coronary Drug Project was conducted before statins existed. Niacin was being compared to placebo in patients with largely uncontrolled dyslipidaemia. The later trials added niacin on top of already-effective statin therapy, in patients whose LDL was already well-controlled. Raising HDL further may simply matter less when LDL is already optimised, a nuance the earlier studies couldn’t capture.
2. The laropiprant problem. The HPS2-THRIVE trial used the niacin-laropiprant combination. Subsequent analysis suggested laropiprant itself may have introduced adverse effects, including increased infection risk and blood sugar disruption, that muddied the results. Blaming niacin alone for that trial’s outcome may not be entirely fair [3].
3. Population differences. Different trials enrolled different patient profiles, varying levels of baseline risk, different co-medications, different durations of treatment and follow-up.
A 2016 meta-regression analysis pushed back against the pessimistic interpretation of the large trials, arguing that niacin *is* still beneficial, particularly when you look at its effects on non-HDL cholesterol and triglycerides rather than HDL alone, and that the aggregate evidence still supports a net cardiovascular benefit [14].
The evidence grade here: Conflicted, the mechanism is clear, the lipid effects are real and well-established, but whether those effects translate to fewer events in statin-treated patients remains genuinely debated. This does not mean niacin doesn’t work. It means the picture is more complex than we once thought.
And then came 2024, and a finding that has genuinely shifted the conversation.
A major study published in *Nature Medicine* used untargeted metabolomics, essentially, scanning thousands of molecules in blood samples simultaneously, to look for novel predictors of cardiovascular events in stable cardiac patients [2]. What they found was unexpected.
Two terminal metabolites of *excess* niacin, molecules produced when the body processes more niacin than it needs, called 2PY (N1-methyl-2-pyridone-5-carboxamide) and 4PY (N1-methyl-4-pyridone-3-carboxamide), were significantly associated with increased risk of major adverse cardiovascular events (MACE) over a three-year follow-up period.
The numbers were notable: – 2PY was associated with a 64% increased MACE risk in a US validation cohort (adjusted HR: 1.64, 95% CI: 1.10–2.42) and a 102% increased risk in a European cohort (HR: 2.02, 95% CI: 1.29–3.18) – 4PY showed similarly elevated risk: HR 1.89 in the US cohort and 1.99 in the European cohort [2]
The discovery cohort included 1,162 stable cardiac patients; two validation cohorts added a further 2,331 (US) and 832 (European) participants.
Crucially, the researchers also found that a genetic variant (rs10496731) strongly associated with higher levels of both 2PY and 4PY was linked to elevated levels of sVCAM-1, a molecule that promotes vascular inflammation and adhesion of inflammatory cells to blood vessel walls, across a meta-analysis of over 106,000 individuals. This provides a plausible biological mechanism: excess niacin metabolites may trigger vascular inflammation, potentially counteracting niacin’s lipid benefits at high doses [2].
A companion editorial in *Nature Reviews Cardiology* noted that this finding was particularly relevant in the context of food fortification, niacin is added to many staple foods including bread and cereals in the UK and US, meaning some people may be chronically consuming more niacin than their bodies can comfortably process, even without taking supplements [1, 5].
The evidence grade: Promising but early, large prospective cohorts, multiple validation steps, and a plausible mechanism. But this is observational data, it shows association, not proven causation. Intervention trials are needed to confirm whether reducing excess niacin actually lowers these metabolites and reduces events.
Here’s where it gets nuanced again, and where the distinction between *dietary niacin* and *pharmacological niacin supplementation* becomes critical.
A large analysis of NHANES data from 2003–2018, covering 80,312 US participants across 15 years, found that higher niacin intake from food was associated with lower all-cause mortality (HR: 0.82, 95% CI: 0.71–0.96 for highest vs. lowest quartile) and lower cardiovascular mortality (OR: 0.80, 95% CI: 0.67–0.96) across the full population [4].
Intriguingly, the benefit was more pronounced, and statistically significant, in women, but not in men. Women in the highest niacin intake quartile showed a 22% lower risk of all-cause mortality (HR: 0.78) and a 25–30% lower risk of cardiovascular mortality compared to those in the lowest quartile [4]. The reasons for this sex difference are not yet well understood.
This analysis reinforces a theme emerging from the totality of the research: getting adequate niacin through food appears protective. The concern raised by the 2024 metabolite data relates specifically to *excess*, the kind generated by high-dose supplementation or heavy fortification, not to normal dietary intake.
The evidence grade: Promising, large, long-duration population dataset, but observational by design. Confounding factors (healthier diets correlate with higher niacin intake) cannot be fully excluded.
One of the most exciting angles in current cardiovascular research doesn’t frame niacin as a lipid drug at all, it frames it as a NAD+ precursor, and asks what declining NAD+ does to the ageing heart.
A 2021 review in *Antioxidants* summarised compelling evidence that NAD+ bioavailability declines with age and metabolic stress in heart and vascular tissue, and that this decline is closely linked to mitochondrial dysfunction, the gradual failure of the tiny energy-generating engines inside heart muscle cells [8].
Experimental models suggest that restoring NAD+ levels, whether through niacin, niacinamide (nicotinamide), or newer precursors, can improve heart function in models of cardiomyopathy, ischaemia-reperfusion injury, atherosclerosis, and diabetic cardiovascular complications [8]. Human trial data in this specific context is limited, and most of the evidence comes from animal or cell studies.
The evidence grade: Early stage, the mechanism is biologically compelling, animal model data is strong, but robust human cardiovascular outcome trials specifically examining NAD+ repletion are still needed.
Intellectual honesty requires us to be clear about the genuine gaps in this field, and there are several significant ones.
The dose question is unresolved. Almost all the high-profile clinical trial data, both the positive and the negative, comes from pharmacological niacin doses (1,000–3,000 mg/day), far above the dietary reference intake of around 16 mg/day for adult men and 14 mg/day for women. The NHANES population data looks at dietary intake in the normal range. The 2PY/4PY metabolite findings appear specifically relevant to excess niacin. We don’t yet have a clear dose-response curve that tells us where “beneficial” ends and “potentially harmful” begins.
The statin interaction is complex. Whether niacin adds cardiovascular benefit on top of modern statin therapy remains genuinely unresolved. The null results from AIM-HIGH and HPS2-THRIVE are real, but so are the methodological concerns about those trials. A 2016 meta-regression suggested niacin still shows benefit, but this remains a live debate in the cardiology literature [14].
Sex differences are unexplained. The NHANES data found significant cardiovascular mortality benefits in women but not in men [4]. This finding needs replication and mechanistic explanation before we can draw firm conclusions.
The 2PY/4PY finding needs intervention trial validation. The 2024 metabolite data is genuinely concerning and plausible, but it is observational. We do not yet have a randomised trial showing that reducing these metabolites, through lower niacin intake, actually reduces cardiovascular events. That trial needs to happen.
The NAD+ cardiovascular story is mostly animal data. The biological rationale is strong, but human cardiovascular outcome data for NAD+ precursor supplementation is limited [8].
So what does a sensible, well-informed person actually do with 70 years of niacin research?
Here is how we’d reason through it, as your brilliant, practically-minded friend who has read all the papers:
1. Getting enough niacin from food is clearly a good thing. The population data is consistent: adequate dietary niacin is associated with lower cardiovascular mortality, particularly in women [4]. Food sources, chicken, turkey, fish, wholegrains, mushrooms, peanuts, should be your primary source. This is not in question.
2. Niacin is a water-soluble B vitamin, at normal dietary and moderate supplementary doses, excess is excreted in urine. At the kind of doses you’d find in a well-formulated B-complex supplement (typically 16–50 mg of niacin), you’re nowhere near the pharmacological territory where the 2PY/4PY concern becomes relevant. Supplementing with a balanced B-complex to support general NAD+ metabolism and fill dietary gaps is safe, practical, and the excess is excreted. There’s no meaningful risk at these doses and no need to test first.
3. High-dose niacin supplementation is a different conversation. Doses above several hundred milligrams per day, particularly the gram-scale doses used in cardiovascular drug trials, should not be self-prescribed without medical involvement. This isn’t excessive caution; the 2024 metabolite data gives us a genuine biological reason to be thoughtful about mega-dosing [2]. This is specifically about pharmacological niacin therapy, not everyday supplementation.
4. The cardiovascular benefits of pharmacological niacin were real in the pre-statin era. If you are not on statins and have significant dyslipidaemia, particularly low HDL or high triglycerides, the historical case for niacin is genuinely strong. If you are already on statins with well-controlled LDL, the additional benefit of high-dose niacin is unclear, and the 2024 metabolite data adds a new reason for caution.
5. The NAD+ story is worth watching. The idea that declining NAD+ contributes to cardiovascular ageing is biologically compelling and increasingly supported by experimental data [8]. This is an evolving area, not yet ready for firm cardiovascular outcome recommendations, but a credible reason to maintain good NAD+ precursor intake through diet and sensible supplementation.
The practical summary: Eat a varied diet rich in natural niacin sources. Take a balanced B-complex daily, it’s safe, water-soluble, and supports the NAD+ pathways your heart and brain depend on. Don’t self-prescribe high-dose niacin therapy for cardiovascular purposes, this is a conversation for your GP or cardiologist, particularly given the emerging metabolite data. And watch this space: the niacin story is still being written, and the next chapter, on NAD+ and the ageing cardiovascular system, is genuinely exciting.
Science is a journey. Niacin’s journey has taken us from a 1955 cholesterol observation to a 2024 discovery about metabolic byproducts and vascular inflammation. Every twist has taught us something valuable. And where we stand today, with a clear case for adequate intake, a nuanced view of supplementation, and a fascinating frontier in NAD+ biology, is a more honest and more useful place than any oversimplified headline could ever take you.
[1] Niacin, food intake and cardiovascular effects. (2024). DOI: 10.1038/s41591-024-03220-2 | https://pubmed.ncbi.nlm.nih.gov/39237629/
[2] A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. (2024). DOI: 10.1038/s41591-023-02793-8 | https://pubmed.ncbi.nlm.nih.gov/38374343/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841810/
[3] Niacin and Stroke: The Role of Supplementation and Emerging Concepts in Clinical Practice, a Narrative Review. (2025). DOI: 10.3390/cimb47060400 | https://pubmed.ncbi.nlm.nih.gov/40699799/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191844/
[4] Exploring the Impact of Niacin Intake on Cardiovascular Outcomes: A Comprehensive Analysis Using NHANES Data (2003–2018). (2024). DOI: 10.31083/j.rcm2511410 | https://pubmed.ncbi.nlm.nih.gov/39618861/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607498/
[5] Metabolic product of excess niacin is linked to increased risk of cardiovascular events. (2024). DOI: 10.1038/s41569-024-01005-1 | https://pubmed.ncbi.nlm.nih.gov/38438588/
[6] Niacin: the only vitamin that reduces cardiovascular events. (2011). https://pubmed.ncbi.nlm.nih.gov/21401825/
[7] Niacin for primary and secondary prevention of cardiovascular events. (2017). https://pubmed.ncbi.nlm.nih.gov/28616955/
[8] Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases. (2021). DOI: 10.3390/antiox10121939 | https://pubmed.ncbi.nlm.nih.gov/34943043/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750485/
[9] Niacin and cholesterol: role in cardiovascular disease (review). (2003). DOI: 10.1016/s0955-2863(02)00284-x | https://pubmed.ncbi.nlm.nih.gov/12873710/
[10] The facts behind niacin. (2011). https://pubmed.ncbi.nlm.nih.gov/21893559/
[11] Niacin in cardiovascular disease: recent preclinical and clinical developments. (2012). https://pubmed.ncbi.nlm.nih.gov/22207729/
[12] Does nicotinic acid (niacin) lower blood pressure? (2009). https://pubmed.ncbi.nlm.nih.gov/19054161/
[13] The resurgence of niacin: from nicotinic acid to niaspan/laropiprant. (2011). https://pubmed.ncbi.nlm.nih.gov/21809737/
[14] Niacin is still beneficial. Implications from an updated meta-regression analysis. (2016). DOI: 10.2143/AC.71.4.3159701 | https://pubmed.ncbi.nlm.nih.gov/27594363/
[15] Nicotinic acid: current status in lipid management and cardiovascular disease prevention. (2014). https://pubmed.ncbi.nlm.nih.gov/24101713/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Mild cognitive impairment is a grey zone between normal age-related memory changes and dementia, and it may be
Quick Read Your brain has a nightly cleaning system called the glymphatic system that removes toxic waste proteins during deep
